BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company’s fourth quarter and full year 2025 earnings report can be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https: ...

Core Insights - Digital healthcare platforms are expanding in consumer wellness and precision medicine, with Hims & Hers Health, Inc. (HIMS) focusing on consumer-first services and Tempus AI, Inc. (TEM) leveraging AI for precision medicine [1][2] Company Overview - HIMS operates a subscription-based platform providing personalized treatments through telehealth and pharmacy services, while TEM utilizes AI on clinical and molecular data for healthcare providers [1][2] - HIMS is expanding into lab testing and diagnostics, enhancing its service offerings in weight management, hormone health, and preventive care [6][7] - TEM is building a multimodal dataset for diagnostics and clinical decision-making, enhancing its value to healthcare providers and researchers [10][12] Stock Performance & Valuation - HIMS has underperformed with a 40.4% decline over the past three months, while TEM has decreased by 24.9% [3] - HIMS is trading at a forward price-to-sales (P/S) ratio of 2.35X, in line with the Medical sector average, whereas TEM's P/S ratio is 7.35X, above the sector average [4] Growth Drivers for Hims & Hers - HIMS is broadening its portfolio, which is expected to increase its addressable market and customer engagement [7] - The company's vertically integrated, data-driven care model enhances personalized treatment plans and quality control [8] - Global expansion and strategic capital deployment are expected to sustain long-term growth and recurring revenue [9] Growth Drivers for Tempus AI - TEM's data advantage from genomic testing and clinical data collection supports its diagnostic offerings and licensing business [10] - Increased adoption of TEM's diagnostic tools reflects integration into clinical workflows, bolstered by regulatory clearances [11] - AI-driven product expansion positions TEM as a technology partner, enhancing its long-term growth narrative [12] Earnings Projections - The Zacks Consensus Estimate for HIMS suggests a 16.8% improvement in EPS for 2026 compared to 2025 [15] - The Zacks Consensus Estimate for TEM indicates a 71.6% improvement in loss per share for 2026 compared to 2025 [18] Price Targets - Analysts project an average price target of $43.85 for HIMS, indicating a potential increase of 51.8% from the last close [20] - For TEM, the average price target is $87.92, suggesting a 34.6% increase from the last close [21] Investment Perspective - HIMS is viewed as a more favorable investment due to its consumer-focused model and expanding service offerings, despite being rated as a Zacks Rank 4 (Sell) [22] - TEM, also rated as Zacks Rank 4, has a compelling long-term growth narrative but trades at a higher valuation, indicating less margin for error [25][26]

Core Viewpoint - Amwell is set to report its second quarter 2025 operating results on August 5, 2025, after market hours, followed by a live conference call to discuss the results and provide a business update [1]. Company Overview - Amwell provides a comprehensive SaaS-based software platform aimed at technology-enabled healthcare, facilitating better access to convenient, affordable, and effective care for patients [3]. - The platform integrates software and services that support various clinical programs, allowing for personalized access to diverse healthcare services [3]. - Amwell has been operational for nearly two decades, serving major healthcare organizations in the U.S. and globally, and is capable of delivering care to millions of patients [3]. Upcoming Events - Company executives will participate in investor conferences, including one-on-one meetings at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 9 [4].

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, offering a unified care platform for payers and health systems [1] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [1] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [1] Upcoming Events - Mark Hirschhorn, CFO and COO of Amwell, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference on May 8 [4] - On June 24, Hirschhorn will also participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City [4]